Literature DB >> 6714286

Dose-dependent pharmacokinetics of aprindine in healthy volunteers.

T Kobari, T Itoh, T Hirakawa, H Namekawa, T Suzuki, T Satoh, N Iida, F Ohtsu, H Hayakawa.   

Abstract

The disposition of aprindine following a single oral dose can best be described by a two-compartment open model. The mean plasma half-life (t 1/2 beta) increased from 8.0 +/- 2.1 h (SD) after a 25 mg dose of 9.4 +/- 2.9 h after 50 mg and to 15.8 +/- 2.6 h after 100 mg, with a decrease in total plasma clearance (Cl/F) and volume of distribution at steady state (V dss/F) and during beta-phase (V d beta/F). The area under plasma concentration-time curve (AUC), maximum plasma concentration (C max) and the amount of unchanged aprindine excreted in the urine increased in a non-linear fashion with the increase in dose. The t 1/2 beta after multiple oral doses showed a 3-fold increase over the single dose value. These results indicate that aprindine shows dose-dependent non-linear kinetics.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6714286     DOI: 10.1007/bf00546721

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Therapeutic effectiveness and plasma levels of aprindine, a new antidysrhythmic drug.

Authors:  J P Van Durme; M G Bogaert; M T Rosseel
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

2.  Model for exchange kinetics of aprindine in man after single and multiple doses.

Authors:  C Delcroix; L Martin; J P Van Durme; H Kesteloot; F Hagemeijer; P Mbuyamba; M Deblecker
Journal:  Acta Cardiol       Date:  1974       Impact factor: 1.718

3.  The pharmacology and clinical evaluation of aprindine a new antiarrhythmic agent.

Authors:  A F Fasola; R Carmichael
Journal:  Acta Cardiol       Date:  1974       Impact factor: 1.718

4.  Aprindine (AC 1802), a new anti-arrhythmic drug.

Authors:  H Kesteloot; W Van Mieghem; H De Geest
Journal:  Acta Cardiol       Date:  1973       Impact factor: 1.718

5.  [Pharmacokinetic characteristics and biodegradation of aprindin in man].

Authors:  L Dodion; J M de Suray; M Deblecker; A Georges
Journal:  Therapie       Date:  1974 Mar-Apr       Impact factor: 2.070

6.  Determination of aprindine in plasma by gas chromatography--mass spectrometry.

Authors:  T Ito; H Namekawa; T Kobari
Journal:  J Chromatogr       Date:  1983-05-13

Review 7.  Aprindine: a review.

Authors:  I Stoel; F Hagemeijer
Journal:  Eur Heart J       Date:  1980-04       Impact factor: 29.983

8.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

Review 9.  Studies with aprindine.

Authors:  D P Zipes; V Elharrar; R F Gilmour; J J Heger; E N Prystowsky
Journal:  Am Heart J       Date:  1980-12       Impact factor: 4.749

Review 10.  Aprindine.

Authors:  P Danilo
Journal:  Am Heart J       Date:  1979-01       Impact factor: 4.749

View more
  3 in total

1.  Dose independent pharmacokinetics of mexiletine in healthy volunteers.

Authors:  T Pringle; J Fox; J A McNeill; C D Kinney; J Liddle; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

2.  The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.

Authors:  T Ebner; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

3.  In vivo evaluation of drug dialyzability in a rat model of hemodialysis.

Authors:  Masaki Fukunaga; Daisuke Kadowaki; Mika Mori; Satomi Hagiwara; Yuki Narita; Junji Saruwatari; Ryota Tanaka; Hiroshi Watanabe; Keishi Yamasaki; Kazuaki Taguchi; Hiroki Ito; Toru Maruyama; Masaki Otagiri; Sumio Hirata
Journal:  PLoS One       Date:  2020-06-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.